Research to Advance Vaccine Safety Program
Page 2

2) The effects of genetic variations on an individual's immune and physiological responses.

3) The determination of biological markers and risk factors that could potentially help in assessing the relationship between certain diseases and licensed vaccines

4) The evaluation of statistical methodologies that are utilized in the process of analyzing vaccine safety.

5) The application of certain genomic and molecular technologies that would help enhance vaccine safety.

In order to support this program, the NIH and CDC are set to administer a maximum annual budget in the amount of $275,000.

The institutions and organizations that will be deemed eligible to participate in this program are the following:

a) Higher Education Institutions such as Public/State Controlled Institutions of Higher Education and Private Institutions of Higher Education

b) Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions

c) Nonprofit organizations other than institutions of higher education

d) For-Profit Organizations such as Small Businesses

e) State Governments, County Governments, City or Township Governments, Special District Governments, Indian/Native American Tribal Governments (Federally Recognized), and Indian/Native American Tribal Governments (Other than Federally Recognized)

f) Independent School Districts, Public Housing Authorities/Indian Housing Authorities, Native American Tribal Organizations (other than Federally recognized tribal governments), Faith-based or Community-based Organizations, and Regional Organizations.

Research to Advance Vaccine Safety Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on grants for youth programs and home improvement grants.

Additional Resources

category - Health Grants

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

The Collaborative Islet Transplantation Registry Program
The National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in order to establish the The Collaborative Islet Transplantation Registry Program wherein both agencies seek to invite applications that intend to continue initiatives started through the Collaborative Islet Transplantation Registry (CITR).

---

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities
The National Institutes of Health has recently formed a partnership with the National Cancer Institute (NCI) in an effort to constitute the Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities wherein both agencies intend to solicit grant application from various eligible researchers who are interested in conducing basic research studies regarding the biological causes and mechanisms of cancer health disparities.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---